

PATIENT INFORMATION

PATIENT NAME: _____ PHONE: _____

DATE OF BIRTH: _____ SEX: ☐ M ☐ F HEIGHT: _____ WEIGHT: _____ ☐ LBS ☐ KG

ALLERGIES: _____ PREFERRED CLINIC: _____

REFERRAL STATUS: ☐ NEW REFERRAL ☐ ORDER CHANGE ☐ ORDER RENEWAL

DIAGNOSIS & CLINICAL DOCUMENTATION

☐ L40.0 Psoriasis Vulgaris

☐ ICD-10 CODE: _____ DESCRIPTION: _____

REQUIRED DOCUMENTATION

☐ Insurance
Information

☐ List of
Medications

☐ Tried & Failed
Therapies

☐ Most Recent History &
Physical

☐ Negative TB screening within 12 months

MEDICATION ORDER

☐ **LOADING:** Ilumya® (tildrakizumab) 100mg via subcutaneous injection at week 0 and 4

☐ **MAINTENANCE:** Ilumya® (tildrakizumab) 100mg via subcutaneous injection every 12 weeks

☒ **REFILL X 12 MONTHS UNLESS OTHERWISE NOTED HERE:** _____

Patient to be observed for 30 minutes following the first injection.

In the event of an adverse reaction occurring in the infusion clinic, utilize the Immersiv Health adverse reaction protocol.

PRESCRIBER INFORMATION

PROVIDER NAME: _____ NPI #: _____

EMAIL: _____ PHONE: _____ FAX: _____

ADDRESS (INCLUDE CITY, STATE, ZIP): _____

SUPERVISING
PHYSICIAN: _____ CONTACT NAME: _____
(IF APPLICABLE)

SIGNATURE: _____ DATE: _____
(NO STAMPS)

SUBSTITUTION PERMITTED

DISPENSE AS WRITTEN